Remetinostat

Overview

Remetinostat (SHP-141) is a hydroxamic acid-based histone deacetylase ( HDAC ) inhibitor. Remetinostat alleviates Imiquimod ( HY-B0180 )-induced psoriatic dermatitis. Remetinostat can be used for study of cutaneous T-cell lymphoma.

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HDAC

Product Information

• Catalog No.: HY-100365
• CAS No.: 946150-57-8
• Molecular Formula: C16H21NO6
• Molecular Weight: 323.34
• Purity: 98.0%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (7.73 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source